Researchers engineered an ionizable lipid nanoparticle system to deliver CAR-encoding mRNA into human T cells with reported efficiency above 90%, producing potent antitumor activity in vitro. The approach aims to avoid viral vectors and electroporation, targeting simpler manufacturing and potentially broader accessibility. The work centers on the nanoparticle’s ability to encapsulate and deliver functional genetic cargo while enabling downstream CAR expression in T cells. In vitro potency supports the feasibility of lipid-mediated mRNA CAR delivery as a platform. If validated in further preclinical and clinical studies, the technology could reshape how CAR-T and CAR-engineered cell therapies are manufactured and dosed, especially where viral manufacturing capacity is limiting.